The following represents disclosure information provided by authors of this abstract. The ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer Planning Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of distinct EGFR downstream pathways on resistance to dual EGFR/ErbB2 combined targeted therapy of lapatinib (LPT) and cetuximab (CTX).
John F. Deeken
Research Funding - GlaxoSmithKline
Corinne Ramos
Employment or Leadership Position - Theranostics Health
Stock Ownership - Theranostics Health
Mary Barcus
Employment or Leadership Position - Theranostics Health
Stock Ownership - Theranostics Health
Jimmy J. Hwang
No relevant relationships to disclose
John Marshall
No relevant relationships to disclose
Deepa Suresh Subramaniam
No relevant relationships to disclose
Aiwu Ruth He
No relevant relationships to disclose
Tingting Zhuang
No relevant relationships to disclose
Rosemarie A. Hardesty
No relevant relationships to disclose
Michael J. Pishvaian
Research Funding - GlaxoSmithKline